Overview

Opioid Drug Interaction Study

Status:
RECRUITING
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
This study will examine the effects of doses of opioid/placebo and doses of alprazolam/placebo, alone and in combination. The primary outcomes are pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) and pharmacokinetic outcomes (from blood samples) to determine the interaction effects of these compounds.
Phase:
PHASE1
Details
Lead Sponsor:
Shanna Babalonis, PhD
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Alprazolam
Oxycodone
oxycodone-acetaminophen